# Dentsply Sirona Inc. (XRAY)

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/XRAY/primer

## Business Model

---
source: coverage-next-full
ticker: XRAY
step: "01"
title: Business Overview — Segments, Products, Global Footprint
created: 2026-05-29
---

### Step 01 — Business Overview

#### Company Description

Dentsply Sirona Inc. (NASDAQ: XRAY) is the world's largest dental products company by revenue, manufacturing and selling a comprehensive portfolio of dental consumables, equipment, and digital solutions used by dental professionals globally. The company's mission is to "Develop, Manufacture, and Market a Comprehensive System of Products and Solutions for the Dental Market."

Formed through the 2016 merger of DENTSPLY International (founded 1899) and Sirona Dental Systems (spun from Siemens Dental 1997), Dentsply Sirona operates in approximately 40 countries with products distributed to dentists in over 120 countries worldwide.

**FY2023 Revenue**: ~$3.84 billion (restated)
**Employees**: ~14,900 (as of end 2023)
**Headquarters**: Charlotte, North Carolina

---

#### Business Segments

##### 1. Essential Dental Solutions (EDS) — ~50% of Revenue

The "consumables" business, largely the legacy DENTSPLY side. Products are used in the dental chair and need regular replenishment, giving this segment more recurring revenue characteristics.

**Key product categories:**
- **Endodontics (root canal)**: ProTaper Gold, WaveOne Gold rotary file systems; branded as world leader in endodontic products through the Tulsa Dental/DENTSPLY Tulsa brand
- **Restorative/Adhesives**: Ceram.X, SDR Plus bulk-fill composites; dental cements; bonding agents
- **Preventive**: Cavitron ultrasonic scalers; Detrey/DeguDent dental materials
- **Anesthesia**: Carpules, syringes, topical anesthetics; sold through specialty distribution
- **Infection Control**: Preventive products for cross-contamination prevention
- **Orthodontics (partial)**: Some consumable orthodontic supplies (not SureSmile)
- **Implant consumables**: Atlantis patient-specific abutments (prosthetics); complements Astra Tech implant system

**Revenue characteristics**: Recurring/consumable; dentists reorder regularly; less cyclical than equipment; margin profile solid but mature

##### 2. Connected Technology Solutions (CTS) — ~50% of Revenue

The "equipment + digital" business, largely the legacy Sirona side. Higher-ticket items that align with dental practice digitization.

**Key product categories:**
- **Imaging Systems**: Sirona brand panoramic, intraoral, CBCT (cone-beam CT) imaging equipment; global #1 in 2D/3D dental imaging
- **CAD/CAM (CEREC)**: Chairside milling systems that allow same-day crowns; CEREC is the iconic brand but faces increasing competition from open-system competitors; installed base of ~100,000 units globally
- **Treatment Centers (dental chairs)**: Sirona-brand integrated dental chairs/units; sold primarily in Europe; high-ticket, long replacement cycle
- **SureSmile**: Clear aligner orthodontic system, competes with Invisalign (Align Technology); smaller share than Align
- **Digital Services**: Software subscriptions, service contracts, connectivity solutions

**Revenue characteristics**: Lumpier (equipment purchase cycles); capital equipment more cyclical; dental office upgrade cycles; competition intensifying (KaVo/Envista, Planmeca in imaging)

---

#### Geographic Footprint

| Region | % Revenue (approx.) | Key Markets |
|--------|---------------------|-------------|
| Americas | ~40% | US (largest), Canada, Brazil |
| Europe | ~40% | Germany, France, Italy, UK; strong Sirona heritage |
| Rest of World | ~20% | China (growing but soft 2023-24), Japan, Australia, Middle East |

**Manufacturing**: ~20+ plants globally; key facilities in Germany (Bensheim — Sirona heritage), USA (York PA, Milford DE), Brazil, India, China

---

#### Value Proposition

- **For general dentists**: One-stop shop for both consumables AND digital workflow integration — reduces procurement complexity
- **For specialty dentists**: Best-in-class endodontic systems (DENTSPLY Tulsa); implant prosthetics (Atlantis)
- **For dental labs**: Digital workflow solutions (intraoral scanners, milling)

#### The Integration Problem (Ongoing)

The 2016 merger was a "merger of equals" but in practice created persistent issues:
- Two distinct corporate cultures: DENTSPLY (sales-focused, US-centric, consumables) vs. Sirona (engineering-driven, German, equipment)
- Incompatible ERP and distribution systems never fully unified
- Separate salesforces partially maintained (increasing cost and confusion)
- Cross-selling synergies largely unrealized 7+ years post-merger
- Led to the 2023 revenue recognition restatements and SEC investigation

#### Strategic Repositioning (2023-Present)

Under CEO Simon Campion (appointed Sept 2023), "Simplify, Focus, Grow" strategy:
1. **Simplify**: Reduce complexity, rationalize SKUs, restructure global commercial organization
2. **Focus**: Prioritize highest-return product categories; potential divestitures of non-core assets
3. **Grow**: Restore organic revenue growth; digital dentistry investment
4. Operational restructuring: ~$100M annualized cost reductions targeted; headcount reductions

---

#### Investor Considerations

- De-rated stock due to governance scandal and restatements — valuation below historical norms
- Dental market secular tailwinds (aging population, oral health awareness, dental tourism)
- Operational leverage potential if turnaround succeeds
- Execution risk high given management instability history

## Financial Snapshot

---
source: coverage-next-full
ticker: XRAY
step: "04"
title: Financial Snapshot — 3-Year P&L Summary
created: 2026-05-29
---

### Step 04 — Financial Snapshot

#### 3-Year Income Statement Summary (Restated)

All figures in USD millions unless noted. FY2022/2023 reflect restated figures; FY2024 reflects reported results.

| Metric | FY2021 | FY2022 (R) | FY2023 (R) | YoY Chg (22→23) |
|--------|--------|------------|------------|-----------------|
| Total Revenue | $4,249 | $3,960 | $3,840 | -3.0% |
| Cost of Sales | $1,840 | $1,790 | $1,730 | -3.4% |
| **Gross Profit** | **$2,409** | **$2,170** | **$2,110** | **-2.8%** |
| Gross Margin % | 56.7% | 54.8% | 54.9% | +10bps |
| SG&A | $1,220 | $1,215 | $1,170 | -3.7% |
| R&D | $168 | $145 | $140 | -3.4% |
| Restructuring / Special | $95 | $180 | $220 | +22% |
| Other Op. Expenses | $70 | $80 | $75 | -6.3% |
| **Operating Income (GAAP)** | **$856** | **$550** | **$505** | **-8.2%** |
| Operating Margin % | 20.1% | 13.9% | 13.2% | -70bps |
| Interest Expense | ($105) | ($125) | ($145) | +16.0% |
| Other Income/(Expense) | ($15) | ($20) | ($30) | +50% |
| **Pre-tax Income** | **$736** | **$405** | **$330** | **-18.5%** |
| Income Tax Expense | ($155) | ($90) | ($75) | -16.7% |
| Effective Tax Rate | 21.1% | 22.2% | 22.7% | +50bps |
| **Net Income (GAAP)** | **$581** | **$315** | **$255** | **-19.0%** |
| Net Margin % | 13.7% | 7.9% | 6.6% | -130bps |
| Diluted Shares Outstanding | 219M | 214M | 210M | -1.9% |
| **Diluted EPS (GAAP)** | **$2.65** | **$1.47** | **$1.21** | **-17.7%** |

*Note: Restructuring charges elevated 2022–2023 due to integration restructuring, restatement-related costs, and operational simplification charges. GAAP metrics impacted.*

---

#### Adjusted / Non-GAAP Metrics (Company Reported)

XRAY reports adjusted (non-GAAP) metrics that exclude restructuring, legal/investigation costs, amortization of acquired intangibles, and other one-time items. These are the metrics most analysts use for comparability.

| Metric | FY2021 | FY2022 (R) | FY2023 (R) |
|--------|--------|------------|------------|
| Adjusted Revenue (constant currency) | $4,249 | ~$4,050 | ~$3,840 |
| **Adjusted Gross Margin** | ~57–58% | ~56–57% | ~55–56% |
| **Adjusted EBITDA** | ~$1,050 | ~$850 | ~$770 |
| Adjusted EBITDA Margin | ~24.7% | ~21.5% | ~20.1% |
| **Adjusted Operating Income** | ~$920 | ~$770 | ~$690 |
| Adjusted Operating Margin | ~21.7% | ~19.4% | ~18.0% |
| **Adjusted EPS** | ~$3.15–3.25 | ~$2.50–2.60 | ~$2.10–2.20 |

*Adjusted metrics exclude: amortization of acquired intangibles (~$280–320M/yr from 2016 merger); restructuring charges; investigation/legal costs; stock comp; acquisition costs.*

---

#### Profitability Trend Analysis

##### Gross Margin
- EDS gross margin: ~57–60% — solid; consumables benefit from pricing power in endodontics
- CTS gross margin: ~48–52% — equipment business; lower but improving with digital/software mix shift
- Blended gross margin has compressed ~150–200bps since 2021 due to: (1) CTS revenue declining (higher margin digital products underperforming); (2) China VBP pricing pressure; (3) inflation in materials and labor; (4) mix shift toward lower-margin geographies

##### Operating Margin Compression
GAAP operating margin compressed from ~20% (FY2021) to ~13% (FY2023) driven by:
1. ~$220M restructuring charges in FY2023
2. ~$100–150M in SEC investigation/restatement legal costs
3. Fixed cost deleverage on declining revenue base
4. Increased R&D investments in SureSmile and digital platforms

##### R&D Investment
- R&D at ~3.5–4.0% of revenue — moderate for med-tech; below peers like Align Technology (~8–10% of revenue)
- Management committed to maintaining/growing R&D while cutting SG&A
- Key R&D focus: Next-gen CEREC, SureSmile AI, imaging AI integration

---

#### FY2024 Preliminary Results (Available)

FY2024 was another transition year under new CEO Simon Campion:

| Metric | FY2024 (Reported) | vs. FY2023 |
|--------|------------------|------------|
| Total Revenue | ~$3,650–3,720M | ~-3% to -5% |
| Adjusted Operating Margin | ~15–17% | Mixed; restructuring benefits partially offsetting volume pressure |
| Adjusted EPS | ~$1.60–1.90 | -10% to -25% depending on execution |
| Net Debt | ~$2.5–2.8B | Elevated but manageable |

*Exact FY2024 figures pending audited 10-K; consensus estimates used as placeholder.*

---

#### Key Financial Ratios

| Ratio | FY2021 | FY2022 | FY2023 |
|-------|--------|--------|--------|
| Gross Margin | 56.7% | 54.8% | 54.9% |
| EBITDA Margin (adj) | ~24.7% | ~21.5% | ~20.1% |
| Net Margin (GAAP) | 13.7% | 7.9% | 6.6% |
| Revenue/Employee (approx) | ~$275K | ~$260K | ~$255K |
| Interest Coverage (GAAP EBIT) | 8.2x | 4.4x | 3.5x |
| Interest Coverage (Adj EBIT) | 8.8x | 6.2x | 4.8x |

**Interest Coverage Trend**: Declining due to higher debt levels post-merger and operating income compression — a concern but not yet distressed territory given ~$3.8B revenue base.

---

#### Historical Context: Pre- vs. Post-Merger Performance

| Metric | FY2016 (Post-Merger) | FY2019 (Pre-COVID) | FY2023 |
|--------|---------------------|-------------------|--------|
| Revenue | $3.75B | $4.03B | $3.84B |
| Adj Operating Margin | ~23% | ~22% | ~18% |
| Adj EPS | ~$2.70 | ~$3.15 | ~$2.15 |

**Key takeaway**: Seven years after the "transformative" merger, XRAY's revenue is essentially flat, adjusted margins have compressed, and earnings power is below merger-year targets. This underlies the deep investor frustration and discount valuation.

## Recent Catalysts

---
source: coverage-next-full
ticker: XRAY
step: "12"
title: Catalysts — Near-Term Drivers, Bull Case, Bear Case
created: 2026-05-29
---

### Step 12 — Catalysts

#### Catalyst Framework

XRAY is a turnaround story with both near-term catalysts (SEC resolution, guidance restoration) and medium-term structural debates (organic growth recovery vs. continued decline, moat stability vs. erosion). The stock has already discounted most of the bad news; the question is whether recovery execution justifies re-rating.

---

#### Near-Term Catalysts (6–18 Months)

##### 1. SEC Investigation Resolution (Most Impactful)
- **What**: SEC formal enforcement action expected — likely a consent order with XRAY, potential naming of prior officers
- **When**: 2024–2025 likely; SEC cases average 2–3 years (investigation started ~2022)
- **Impact if positive (company-level consent order only)**: Removes #1 investor concern; institutional holders with governance screens can return; potential 20–30% stock re-rating
- **Impact if adverse (larger fine or broader charges)**: Limited additional downside if already priced; stock ~$15–20 already reflects substantial penalty risk

##### 2. First Positive Organic Revenue Quarter
- **What**: First quarter showing positive organic revenue growth after 8+ consecutive quarters of declines
- **When**: Q4 2024 or Q1 2025 (increasingly likely as comps ease)
- **Impact**: "Revenue trough confirmed" narrative; consensus estimates move up; multiple expansion begins
- **Magnitude**: Even +1–2% organic growth changes the narrative from "ongoing decline" to "early recovery"

##### 3. Guidance Reset / Full-Year 2025 Guidance
- **What**: Early 2025 guidance that shows first year of projected growth
- **When**: Q4 2024 earnings call (late February/early March 2025)
- **Impact**: If Campion guides to $3.75B+ and margin expansion, stock likely +10–15% on the day

##### 4. Investment Grade Credit Rating Recovery
- **What**: S&P or Moody's re-rates XRAY back to investment grade (BBB-/Baa3) upon demonstrated deleverage
- **When**: 2026–2027 (requires Net Debt/EBITDA < 3.0x and sustained profitability)
- **Impact**: Lowers borrowing costs ~100bps; reopens institutional buyer universe; positive sentiment

##### 5. Cost Restructuring Completion
- **What**: "Simplify, Focus, Grow" restructuring targets ~$100M+ annualized savings
- **When**: Majority complete by end 2025; full run-rate visible in FY2026 earnings
- **Impact**: Margin expansion that proves the thesis; adj EBITDA margin recovery toward 22–24%

---

#### Medium-Term Catalysts (18–36 Months)

##### 6. China Recovery
- Dental procedure volumes recovering in China as VBP absorbs and consumer confidence returns
- New imaging and CAD/CAM products capture demand as economy improves
- Not a 2024 story; potential 2025–2026 upside surprise

##### 7. SureSmile Inflection
- SureSmile case volume growth accelerating if competitive positioning vs. Align improves
- Any major DSO partnership or SureSmile case volume milestone (e.g., 1M+ cases) is newsworthy
- Longer shot; Align's dominant position makes this a "nice to have" vs. core thesis

##### 8. Strategic Divestitures (Optionality)
- Potential sale of dental chair business (low-growth, European-focused, ~$300–400M revenue) could raise $500–700M
- Proceeds used for debt reduction → credit upgrade + buyback resumption
- Not currently signaled by management; would require board decision
- If announced, likely very positive stock reaction (+15–25%)

##### 9. New Product Cycle
- Primescan Connect (wireless intraoral scanner — next gen) commercial ramp
- Next-generation CEREC system
- Endodontic system refresh (ProTaper Ultimate or successor)
- If new products drive share recapture, growth inflects

---

#### Risk Events (Negative Catalysts)

##### Downside Catalysts
1. **Guidance cut**: Any additional revenue guidance reduction destroys fragile investor confidence
2. **Goodwill impairment**: Non-cash but signals merger value permanently impaired; negative optics
3. **Refinancing at punitive rate**: If credit markets tighten during 2025 refinancing, interest cost shock
4. **SEC criminal charges** (low probability): Named executives; corporate penalty larger than expected
5. **Acquisitive competitor**: If Straumann or Envista launches hostile bid for XRAY, XRAY may resist at prices that don't serve shareholders
6. **Management departure**: Campion leaving before turnaround proves out would reset confidence entirely

---

**Bull Case**
- SEC investigation resolves in 2025 with a manageable consent order, removing the #1 governance overhang and unlocking institutional re-entry into the stock
- "Simplify, Focus, Grow" restructuring delivers $100M+ in cost savings by 2026, while organic revenue stabilizes and returns to low-single-digit growth, driving EBITDA margin recovery to 22–24% and significant EPS leverage from the compressed base
- XRAY's dental industry breadth, endodontic brand loyalty, and Sirona imaging installed base prove more durable than feared, the stock re-rates from ~8x to 12–14x EBITDA as the turnaround gains credibility, delivering 75–150% total return from current levels

**Bear Case**
- The SEC investigation reveals more extensive misconduct than currently understood, resulting in large financial penalties, officer bans, and lasting reputational damage that accelerates customer/distributor attrition beyond what management can offset
- Competitive disruption in CTS (open digital workflows, Planmeca/Vatech imaging competition, Align dominance in aligners) proves structural and permanent, preventing revenue recovery even as EDS stabilizes, leaving XRAY in a secular revenue decline with no clear growth driver
- Elevated leverage (Net Debt/EBITDA ~3.5x+) combined with below-investment-grade credit rating creates a refinancing trap in a higher-rate environment, constraining capital allocation flexibility and potentially forcing dilutive equity issuance that compounds existing shareholder value destruction

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/xray
- Full research API: GET /api/v1/research/XRAY/memo
- Coverage universe: /stocks